Compare T Rowe Price Group Inc (TROW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs GeneDx Holdings Corp — how do they compare? T Rowe Price Group Inc trades at $111.36 (market cap $24.26B), while GeneDx Holdings Corp trades at $82.29 (market cap $2.44B). The key difference: T Rowe Price Group Inc is far larger — about 9.9× GeneDx Holdings Corp's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TROW | WGS | |
|---|---|---|
Market Cap | $24.26B | $2.44B |
Sector | Financials | Technology |
52-Week High | $121.68 | $167.51 |
52-Week Low | $86.19 | $34.51 |
Enterprise Value | $21.46B | $2.48B |
Dividend Yield | 4.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price Group (TROW) trades at $113.77, down 0.22% on the day, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a 29.26% net income margin and a P/E of 11.42, indicating potential undervaluation. Recent Q2 2026 earnings beat expectations at $2.57 per share, supported by record assets under management and higher advisory fees, though expenses and net outflows remain headwinds.
The outlook is cautiously optimistic with earnings growth and dividend stability offering upside, but risks include expense pressures and market volatility. Analyst consensus is a Hold with a $112.17 price target, near the current price, suggesting limited near-term momentum. Institutional activity shows mixed positioning, reflecting balanced risk-reward.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
